Selecting systemic treatment for metastatic neuroendocrine tumors of the lung-current evidence and clinical...

Area of Science:

• Oncology
• Endocrinology
• Pulmonology

Background:

• Lung neuroendocrine neoplasms (NEN) encompass both slow-growing neuroendocrine tumors (NET) and aggressive small cell lung cancer (SCLC).
• Metastatic lung NET require distinct treatment strategies compared to other lung cancers.
• Current treatment guidelines offer multiple options but lack clear sequencing for lung NET.

Purpose of the Study:

• To critically evaluate existing evidence for metastatic lung NET treatment.
• To identify patient subgroups with unmet therapeutic needs.
• To inform personalized treatment strategies by integrating scientific findings and clinical features.

Main Methods:

• Systematic review of clinical trial data for lung NET.
• Analysis of patient characteristics, inclusion/exclusion criteria, and outcome metrics.
• Evaluation of treatment options including somatostatin analogs (SSA), everolimus, chemotherapy, and peptide receptor radionuclide therapy (PRRT).

Main Results:

• Treatment selection for lung NET is multifactorial, depending on tumor grade, burden, progression, and somatostatin receptor (SSTR) expression.
• No definitive treatment sequence is established for metastatic lung NET.
• Several patient subgroups may have unmet therapeutic needs requiring further investigation.

Conclusions:

• Personalized treatment approaches are crucial for managing metastatic lung NET.
• Integrating latest scientific evidence with individual patient clinical features is essential for optimal care.
• Ongoing clinical trials are vital for addressing therapeutic gaps in specific lung NET patient subgroups.